UNSPSC 51282513: Ceftezole

This classification denotes a cephalosporin antibiotic with the molecular formula C13H12N8O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z86SYP11W, chemically known as (6r,7r)-8-oxo-7-(2-(1h-tetrazol-1-yl)acetamido)-3-((1,3,4-thiadiazol-2-ylthio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid but generally known as ceftezole, which bears US NIH Compound Identifier 65755. European Medicines Agency schedules Ceftezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07424MIG.

UNSPSC 51282513 Ceftezole is a Commodity code, but the recent state and local opportunities tagged under it do not involve ceftezole procurement — instead, they reflect a broader mix of pharmaceutical, medical supply, and prescription program solicitations across health departments, municipalities, and cooperative purchasing alliances. The code shows a significant mismatch between its nominal scope and what agencies are actually buying under the tag, suggesting either classification drift or tag misapplication in the source data. When pharmaceutical purchasing does occur in the state and local space, it tends to be bundled into larger medical and first aid supply contracts, generic multi-source drug programs, or emerging direct-to-manufacturer prescription initiatives rather than isolated active pharmaceutical ingredient or specialty antibiotic buys.

The recent opportunities span Texas Health and Human Services (an RFI on direct-to-manufacturer prescription programs), the City of Tampa (a $700,000 IFB for medical and first aid supplies with a response date of March 13, 2026, designated as sheltered for Small Local Business Enterprises with a 5% bid discount), the Minnesota Multistate Cooperative Purchasing Alliance (an RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, covering multiple state and local jurisdictions including Oregon), and Seminole County, Florida (an IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline). Activity is concentrated in the Southeast and Midwest, with Texas and Minnesota showing the most recent coordinated procurement efforts. The code does not reliably signal ceftezole or narrow-spectrum antibiotic demand; business development professionals should treat this code as noisy and cross-reference actual pharmaceutical ingredient sourcing through broader medical supply, pharmacy benefit, or generic drug cooperative purchasing codes instead.